Anti-F2/3 serum antibodies as cure markers in children with congenital Trypanosoma cruzi infection;Anticuerpos anti-F2/3 como marcador de curacion en niños con infeccion congenita por Trypanosoma cruzi

Medicina

Volumn 63, Issue 1, 2003, Pages 37-40

  Altcheh, Jaime ^a   Corral, Ricardo ^a   Biancardi, Miguel A ^a   Freilij, Hector ^a  

^a HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

Author keywords

Anti F2 3 serum antibodies; Chemotherapy; Congenital Chagas' disease; Cure; Mucin like glycoconjugates; Serology

Indexed keywords

BENZNIDAZOLE; BIOLOGICAL MARKER; EPITOPE; IMMUNOGLOBULIN; PARASITE ANTIGEN;

ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; CELL KINETICS; CHAGAS DISEASE; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CONVALESCENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; SEROLOGY; TREATMENT OUTCOME; TRYPANOSOMA CRUZI; TRYPOMASTIGOTE;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; BIOLOGICAL MARKERS; CHAGAS DISEASE; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INFANT; INFANT, NEWBORN; TRYPANOSOMA CRUZI;

EID: 0037248029     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Moncayo A. Progreso en la interrupción de la transmisión de la enfermedad de Chagas en los países del Cono Sur. Medicina (Buenos Aires), 1999; 59: 120-4.
2. Freilij H, Altcheh J. Chagas congénito. En: Storino R, Milei J (eds). Enfermedad de Chagas. Ed. Buenos Aires: Mosby Doyma 1994; p 267-78.
3. Tratamiento etiológico de la enfermedad de Chagas. Conclusiones de una Consulta Técnica. Documento OPS/HCP/HCT/140/1999.
4. Freilij H, Altcheh J. Congenital Chagas' disease: Diagnostic and clinical aspects. Clin Infect Dis 1995; 21: 551-5.
5. Freilij H, Altcheh J. Respuesta terapéutica al nifurtimox en pacientes de edad pediátrica con enfermedad de Chagas crónica. Rev Patol Trop (Brasil) 1998; 27: 17-9.
6. Galvâo L, Nunes R, Cançado J, Brener Z, Krettli A. Lytic antibody titre as a means of assessing cure after treatment of Chagas disease: a 10 years follow-up study. Trans R Soc Trop Med Hyg 1993; 87: 220-3.
7. Krettli AU, Cançado JR, Brener Z. Effect of specific chemotherapy on the levels of lytic antibodies in Chagas disease. Trans R Soc Trop Med Hyg 1982; 76: 334-40.
8. Almeida IC, Krautz GM, Krettli AU, Travassos LR. Glycoconjugates of Trypanosoma cruzi: A 74kD antigen of trypomastigotes specifically reacts with lytic anti-α-galactosyl antibodies from patients with chronic Chagas disease. J Clin Lab Anal 1993; 7: 307-16.
9. Krettli AU. Diagnosis of Trypanosoma cruzi chronic infections in humans: Usefulness of the complement regulatory protein antigens and lytic antibodies in the control of cure. Mem Inst Oswaldo Cruz 1999; 94: 301-4.
10. Krautz GM, Kissinger JC, Krettli AU. The targets of the lytic antibody response against Trypanosoma cruzi. Parasitol. Today 2000; 16: 31-4.
11. Almeida I, Ferguson M, Schenkman S, Travassos L. Lytic anti-galactosyl antibodies from patientes with chronic Chagas disease recognize novel O-linked oligosaccharides on mucin-like glycosyl-phosphatidylinositol anchored glycoproteins of Trypanosoma cruzi. Biochem J 1994; 304: 793-802.
12. Villalta F and Kierszenbaun F. Growth of isolated amastigotes of Trypanosoma cruzi in cell-free medium. J Protozool 1982; 29: 570-6.
13. Almeida I, Rodrigues E, Travassos L. Chemiluminescent immunoassays: discrimination between the reactivities of natural and human patient antibodies with antigens from eukaryotic pathogens, Trypanosoma cruzi and Paracoccidioides brasiliensis. J Clin Lab Anal 1994; 8: 424-31.
14. De Andrade SS, de Andrade JG, Martelli CM. Randomized trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 1996; 348: 1407-13.
15. Sosa Estani S, Segura EL, Porcel BM, et al. Chemotherapy with benznidazol in children in undetermined phase of Chagas disease. Am J Trop Med Hyg 1998; 59: 526-9.